The human retrovirus XMRV in prostate cancer and chronic fatigue syndrome - Nature Reviews Urology
- ️Klein, Eric A.
- ️Tue Jun 01 2010
Rous, P. A sarcoma of the fowl transmissible by an agent separable from the tumor cells. J. Exp. Med. 13, 397–411 (1911).
Fan, H. A new human retrovirus associated with prostate cancer. Proc. Natl Acad. Sci. USA 104, 1449–1450 (2007).
Carpten, J. et al. Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat. Genet. 30, 181–184 (2002).
Urisman, A. et al. Identification of a novel gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant. PLoS Pathog. 2, e25 (2006).
Nelson, W. G., De Marzo, A. M. & Isaacs, W. B. Prostate cancer. N. Engl. J. Med. 349, 366–381 (2003).
De Marzo, A. M. et al. Inflammation in prostate carcinogenesis. Nat. Rev. Cancer 7, 256–269 (2007).
Sfanos, K. S. et al. A molecular analysis of prokaryotic and viral DNA sequences in prostate tissue from patients with prostate cancer indicates the presence of multiple and diverse microorganisms. Prostate 68, 306–320 (2008).
Dennis, L. K., Lynch, C. F. & Torner, J. C. Epidemiologic association between prostatitis and prostate cancer. Urology 60, 78–83 (2002).
Dennis, L. K. & Dawson, D. V. Meta-analysis of measures of sexual activity and prostate cancer. Epidemiology 13, 72–79 (2002).
Huang, W. Y. et al. Sexually transmissible infections and prostate cancer risk. Cancer Epidemiol. Biomarkers Prev. 17, 2374–2381 (2008).
Sutcliffe, S. et al. Sexually transmitted infections and prostatic inflammation/cell damage as measured by serum prostate specific antigen concentration. J. Urol. 175, 1937–1942 (2006).
Platz, E. A. & De Marzo, A. M. Epidemiology of inflammation and prostate cancer. J. Urol. 171, S36–S40 (2004).
Putzi, M. J. & De Marzo, A. M. Morphologic transitions between proliferative inflammatory atrophy and high-grade prostatic intraepithelial neoplasia. Urology 56, 828–832 (2000).
Sfanos, K. S., Wilson, B. A., De Marzo, A. M. & Isaacs, W. B. Acute inflammatory proteins constitute the organic matrix of prostatic corpora amylacea and calculi in men with prostate cancer. Proc. Natl Acad. Sci. USA 106, 3443–3448 (2009).
Klein, E. A., Casey, G. & Silverman, R. Genetic susceptibility and oxidative stress in prostate cancer: integrated model with implications for prevention. Urology 68, 1145–1151 (2006).
Casey, G. et al. RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nat. Genet. 32, 581–583 (2002).
Rennert, H. et al. A novel founder mutation in the RNASEL gene, 471delAAAG, is associated with prostate cancer in Ashkenazi Jews. Am. J. Hum. Genet. 71, 981–984 (2002).
Rokman, A. et al. Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in patients and families with prostate cancer. Am. J. Hum. Genet. 70, 1299–1304 (2002).
Downing, S. R. et al. Mutations in ribonuclease L gene do not occur at a greater frequency in patients with familial prostate cancer compared with patients with sporadic prostate cancer. Clin. Prostate Cancer 2, 177–180 (2003).
Wiklund, F. et al. Genetic analysis of the RNASEL gene in hereditary, familial, and sporadic prostate cancer. Clin. Cancer Res. 10, 7150–7156 (2004).
Maier, C. et al. Mutation screening and association study of RNASEL as a prostate cancer susceptibility gene. Br. J. Cancer 92, 1159–1164 (2005).
Li, H. & Tai, B. C. RNASEL gene polymorphisms and the risk of prostate cancer: a meta-analysis. Clin. Cancer Res. 12, 5713–5719 (2006).
Silverman, R. H. Viral encounters with OAS and RNase L during the IFN antiviral response. J. Virol. 81, 12720–12729 (2007).
Xiang, Y. et al. Effects of RNase L mutations associated with prostate cancer on apoptosis induced by 2',5'-oligoadenylates. Cancer Res. 63, 6795–6801 (2003).
Malathi, K., Paranjape, J. M., Ganapathi, R. & Silverman, R. H. HPC1/RNASEL mediates apoptosis of prostate cancer cells treated with 2',5'-oligoadenylates, topoisomerase I inhibitors, and tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res. 64, 9144–9151 (2004).
Castelli, J. C. et al. The role of 2'-5' oligoadenylate-activated ribonuclease L in apoptosis. Cell Death Differ. 5, 313–320 (1998).
Wang, D. et al. Microarray-based detection and genotyping of viral pathogens. Proc. Natl Acad. Sci. USA 99, 15687–15692 (2002).
Dong, B. et al. An infectious retrovirus susceptible to an IFN antiviral pathway from human prostate tumors. Proc. Natl Acad. Sci. USA 104, 1655–1660 (2007).
Kim, S. et al. Integration site preference of xenotropic murine leukemia virus-related virus, a new human retrovirus associated with prostate cancer. J. Virol. 82, 9964–9977 (2008).
Schlaberg, R., Choe, D. J., Brown, K. R., Thaker, H. M. & Singh, I. R. XMRV is present in malignant prostatic epithelium and is associated with prostate cancer, especially high-grade tumors. Proc. Natl Acad. Sci. USA 106, 16351–16356 (2009).
Knouf, E. C. et al. Multiple integrated copies and high-level production of the human retrovirus XMRV from 22Rv1 prostate carcinoma cells. J. Virol. 83, 7353–7356 (2009).
Hohn, O. et al. Lack of evidence for xenotropic murine leukemia virus-related virus (XMRV) in German prostate cancer patients. Retrovirology 6, 92 (2009).
Lombardi, V. C. et al. Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome. Science 326, 585–589 (2009).
Goff, S. in Retroviridae: The Retroviruses and Their Replication Fields Virology 5th edn (eds Knipe, D. & Howley, P. M.) 1999–2069 (Lippincott, Williams & Wilkins, 2007).
Li, W. H., Gu, Z., Wang, H. & Nekrutenko, A. Evolutionary analyses of the human genome. Nature 409, 847–849 (2001).
Arnold, R. S. et al. XMRV infection in prostate cancer patients: novel serologic assay and correlation with PCR and FISH. Urology 75, 755–761 (2010).
Groom, H. C. et al. Absence of xenotropic murine leukaemia virus-related virus in UK patients with chronic fatigue syndrome. Retrovirology 7, 10 (2010).
Furuta, R. A. The prevalence of xenotropic murine leukemia virus-related virus in healthy blood donors in Japan. Presented at the Cold Spring Harbor Laboratory meeting on retroviruses, 18–23 May, 2009.
Fischer, N. et al. Prevalence of human gammaretrovirus XMRV in sporadic prostate cancer. J. Clin. Virol. 43, 277–283 (2008).
D'Arcy, F. et al. No evidence of XMRV in Irish prostate cancer patients with R462Q mutation. Eur. Urol. Suppl. 7, 271 (2008).
Devanur, L. D. & Kerr, J. R. Chronic fatigue syndrome. J. Clin. Virol. 37, 139–150 (2006).
Suhadolnik, R. J. et al. Biochemical evidence for a novel low molecular weight 2-5A-dependent RNase L in chronic fatigue syndrome. J. Interferon Cytokine Res. 17, 377–385 (1997).
Demettre, E. et al. Ribonuclease L proteolysis in peripheral blood mononuclear cells of chronic fatigue syndrome patients. J. Biol. Chem. 277, 35746–35751 (2002).
Erlwein, O. et al. Failure to detect the novel retrovirus XMRV in chronic fatigue syndrome. PLoS ONE 5, e8519 (2010).
van Kuppeveld, F. J. et al. Prevalence of xenotropic murine leukaemia virus-related virus in patients with chronic fatigue syndrome in the Netherlands: retrospective analysis of samples from an established cohort. BMJ 340, c1018 (2010).
McCormick, A. L. et al. Quantification of reverse transcriptase in ALS and elimination of a novel retroviral candidate. Neurology 70, 278–283 (2008).
Voisset, C., Weiss, R. A. & Griffiths, D. J. Human RNA “rumor” viruses: the search for novel human retroviruses in chronic disease. Microbiol. Mol. Biol. Rev. 72, 157–196 (2008).
Coffin, J. M. & Stoye, J. P. Virology. A new virus for old diseases? Science 326, 530–531 (2009).
Proietti, F. A., Carneiro-Proietti, A. B., Catalan-Soares, B. C. & Murphy, E. L. Global epidemiology of HTLV-I infection and associated diseases. Oncogene 24, 6058–6068 (2005).
Courouce, A. M., Pillonel, J., Lemaire, J. M., Maniez, M. & Brunet, J. B. Seroepidemiology of HTLV-I/II in universal screening of blood donations in France. Aids 7, 841–847 (1993).
Tlsty, T. D. & Hein, P. W. Know thy neighbor: stromal cells can contribute oncogenic signals. Curr. Opin. Genet. Dev. 11, 54–59 (2001).
Bhowmick, N. A., Neilson, E. G. & Moses, H. L. Stromal fibroblasts in cancer initiation and progression. Nature 432, 332–337 (2004).
Kim, S. et al. Fidelity of target site duplication and sequence preference during integration of xenotropic murine leukemia virus-related virus. PLoS ONE 5, e10255 (2010).
Dong, B. & Silverman, R. H. Androgen stimulates transcription and replication of XMRV (xenotropic murine leukemia virus-related virus). J. Virol. 84, 1648–1651 (2009).
Rodriguez, J. J. & Goff, S. P. Xenotropic murine leukemia virus-related virus establishes an efficient spreading infection and exhibits enhanced transcriptional activity in prostate carcinoma cells. J. Virol. 84, 2556–2562 (2009).
Stieler, K. et al. Host range and cellular tropism of the human exogenous gammaretrovirus XMRV. Virology 399, 23–30 (2010).
Sharma, P. et al. Organ and cell lineage dissemination of XMRV in rhesus macaques during acute and chronic infection. Presented at the 17th Conference on Retroviruses and Opportunistic Infections, 2010.
Mani, R. S. et al. Induced chromosomal proximity and gene fusions in prostate cancer. Science 326, 1230 (2009).
Metzger, M. J., Holguin, C. J., Mendoza, R. & Miller, A. D. The prostate cancer-associated human retrovirus XMRV lacks direct transforming activity but can induce low rates of transformation in cultured cells. J. Virol. 84, 1874–1880 (2009).
Schlecht-Louf, G. et al. Retroviral infection in vivo requires an immune escape virulence factor encrypted in the envelope protein of oncoretroviruses. Proc. Natl Acad. Sci. USA 107, 3782–3787 (2010).
Battini, J. L., Rasko, J. E. & Miller, A. D. A human cell-surface receptor for xenotropic and polytropic murine leukemia viruses: possible role in G protein-coupled signal transduction. Proc. Natl Acad. Sci. USA 96, 1385–1390 (1999).
Yan, Y., Liu, Q. & Kozak, C. A. Six host range variants of the xenotropic/polytropic gammaretroviruses define determinants for entry in the XPR1 cell surface receptor. Retrovirology 6, 87 (2009).
Groom, H. C., Yap, M. W., Galao, R. P., Neil, S. J. & Bishop, K. N. Susceptibility of xenotropic murine leukemia virus-related virus (XMRV) to retroviral restriction factors. Proc. Natl Acad. Sci. USA 107, 5166–5171 (2010).
Paprotka, T. et al. Inhibition of xenotropic murine leukemia virus-related virus by APOBEC3 proteins and antiviral drugs. J. Virol. 84, 5719–5729 (2010).
Munch, J. et al. Semen-derived amyloid fibrils drastically enhance HIV infection. Cell 131, 1059–1071 (2007).
Roan, N. R. et al. The cationic properties of SEVI underlie its ability to enhance HIV infection. J. Virol. 285, 1861–1869 (2008).
Hong, S. et al. Fibrils of prostatic acid phosphatase fragments boost infections by XMRV, a human retrovirus associated with prostate cancer. J. Virol. 83, 6995–7003 (2009).
Singh, I., Gorzynski, J. E., Drobrysheva, D., Bassit, L. & Shinazi, R. F. Raltegravir is a potent inhibitor of XMRV, a virus implicated in prostate cancer and chronic fatigue syndrome. PLoS ONE 5, e948 (2010).
Sakuma, R., Sakuma, T., Ohmine, S., Silverman, R. H. & Ikeda, Y. Xenotropic murine leukemia virus-related virus is susceptible to AZT. Virology 397, 1–6 (2009).
Qui, X. et al. XMRV: examination of viral kinetics, tissue tropism, and serological markers of infection. Presented at the 17th Conference on Retroviruses and Opportunistic Infections, 2010.
Barquinero, J., Eixarch, H. & Perez-Melgosa, M. Retroviral vectors: new applications for an old tool. Gene Ther. 11 (Suppl. 1), S3–S9 (2004).
Dong, B., Silverman, R. H. & Kandel, E. S. A natural human retrovirus efficiently complements vectors based on murine leukemia virus. PLoS ONE 3, e3144 (2008).
Stang, A. et al. Unintended spread of a biosafety level 2 recombinant retrovirus. Retrovirology 6, 86 (2009).
Denner, J. Detection of a gammaretrovirus, XMRV, in the human population: open questions and implications for xenotransplantation. Retrovirology 7, 16 (2010).
Feng, H., Shuda, M., Chang, Y. & Moore, P. S. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 319, 1096–1100 (2008).
Cobbs, C. S. et al. Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res. 62, 3347–3350 (2002).